To exclude possible effects on VSVg-specific cellular entry and firefly luciferase activity, F2 was tested for its ability to block infection of CEM-GFP lymphocytic indicator cells by a replication-competent HIV-1 vector with a wild-type CXCR4-tropic HIV-1 envelope glycoprotein[10]. The gene discussed is ERVW-1; the disease is infection.